Despite existing treatments and advancements in medicine, 10–30% of people with lupus nephritis reach end-phase kidney failure.
As this condition can be fatal, patients with lupus nephritis are in need of more treatment options. The positive results of a phase 3 clinical trial led by Richard Furie, MD, chief of rheumatology at Northwell Health, indicate that the drug belimumab (brand name Benlysta) helps manage lupus nephritis.
If approved by the Food and Drug Administration (FDA), belimumab would be the first drug approved by the FDA to treat lupus nephritis.
Read more on themighty.com